表紙
市場調査レポート

インスリンデテミルの中国市場

Investigation Report on China Insulin Detemir Market, 2010-2019

発行 China Research and Intelligence 商品コード 332308
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
インスリンデテミルの中国市場 Investigation Report on China Insulin Detemir Market, 2010-2019
出版日: 2015年06月04日 ページ情報: 英文 20 Pages
概要

インスリンデテミルは、Novo Nordiskによって製造される新世代の持効型溶解ヒトインスリンアナログで、2005年に米国市場に登場し、2014年には20億米ドルの売上げを記録しました。インスリンデテミルは、2009年に中国市場に参入して以来、その売上げを急速に伸ばしており、2010年には300万人民元にも満たなかった売上げは、2014年には6800万人民元に達しました。

当レポートでは、中国におけるインスリンデテミル市場の規模と今後の見通し、主要製薬会社および剤形別の市場シェア、販売価格などの情報を提供しています。

第1章 インスリンデテミルの関連概念

  • 適応
  • 世界市場における発展

第2章 中国におけるインスリンデテミルの市場プロファイル

  • インスリンデテミルの特許および承認状況
  • 主要製薬会社
  • 市場規模

第3章 中国におけるインスリンデテミルの販売額

  • 総販売額
  • 地域別の販売額

第4章 中国におけるインスリンデテミルの販売量

  • 総販売量
  • 地域別の販売数

第5章 中国におけるインスリンデテミルの主要製薬会社の市場シェア調査

  • 販売額ベースの市場シェア
  • 販売量ベースの市場シェア

第6章 中国におけるインスリンデテミルの剤形別の市場規模調査

  • 剤形別の市場シェア:販売額ベース
  • 剤形別の市場シェア:販売量ベース

第7章 中国の病院におけるインスリンデテミルの基準価格

第8章 中国市場におけるインスリンデテミルの主要製薬会社

第9章 中国におけるインスリンデテミルの市場見通し

  • 市場規模の予測
  • 競合情勢の予測
目次
Product Code: 1506201

As economy develops and living standards improve, Chinese people's dietary pattern changes with heat, protein and fat coming from animals instead of vegetables, resulting in excess heat. Besides, people's ignorance of diabetes and the drop in physical activities lead to obesity. Other factors like the ageing population also play a role in the rapid increase of diabetes incidence in China.

Ever since insulin determir came into being, it has brought hope to patients with diabetes and has played an important role in diabetes treatment. With the advances in diabetes studies, the appearance of insulin analogue again cast new light on diabetes treatment. Insulin analogues include short-acting insulin analogues, long-acting insulin analogues and premixed insulin analogues, among which long-acting insulin analogues consist of insulin glargine and insulin determir.

Insulin Detemir, a new long-acting soluble (avoiding the common side effects of non-solvent insulin) human insulin analogue, was made by Novo Nordisk through energetic engineering. It came into the American market in 2005 and brought in sales revenue of USD 2 billion around the world in 2014.

According to CRI's market survey, insulin detemir develops fast after entering China in 2009, annual sales rising from less than CNY 3 million in 2010 to CNY 68 million in 2014 and CAGR during this period reaching up to 135%. Currently, insulin detemir market in China is monopolized by Novo Nordisk. The price range of 300 IU 3 ML insulin determir (one injection per package) in Chinese sample hospitals is CNY 193-205/package and there is little difference between citites.

The market size of insulin detemir in China is expected to keep growing in the next few years.

Readers can get at least the following information through this report:

  • market share of manufacturers of insulin detemir in Chinese market
  • price of insulin detemir in Chinese market
  • major manufacturers of insulin detemir in China
  • share of different dosage forms of insulin detemir in Chinese market
  • market outlook of insulin detemir in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Insulin Detemir

  • 1.1. Indication
  • 1.2. Developments in Global Market

2. Market Profile of Insulin Detemir in China

  • 2.1. Patent and Approval Status of Insulin Detemir in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Value of Insulin Detemir in China, 2010-2014

  • 3.1. Overall Sales Value
  • 3.2. Sales Value by Regions

4. Survey on Sales Volume of Insulin Detemir in China, 2010-2014

  • 4.1. Overall Sales Volume
  • 4.2. Sales Volume by Regions

5. Survey on Market Share of Major Manufacturers of Insulin Detemir in China, 2010-2014

  • 5.1. Market Share by Sales Value
  • 5.2. Market Share by Sales Volume

6. Survey on Market Size of Dosage Forms of Insulin Detemir in China, 2010-2014

  • 6.1. Market Share of Different Dosage Forms by Sales Value
  • 6.2. Market Share of Different Dosage Forms by Sales Volume

7. Reference Price of Insulin Detemir in Chinese Hospitals in 2013

8. Major Manufacturers of Insulin Detemir in Chinese Market, 2010-2014

9. Market Outlook of Insulin Detemir in China, 2014-2018

  • 9.1. Forecast of Market Size
  • 9.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Insulin Detemir in China
  • Chart Sales Status of Insulin Detemir in China, 2010-2014
  • Chart Sales Value of Insulin Detemir in China, 2010-2014
  • Chart Sales Value of Insulin Detemir in Some Regions in China, 2010-2014
  • Chart Sales Volume of Insulin Detemir in China, 2010-2014
  • Chart Sales Volume of Insulin Detemir in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Insulin Detemir Made by Novo Nordisk (Denmark) in China, 2010-20114
  • Chart Sales Value and Market Share of Insulin Detemir Made by Novo Nordisk (the US) in China, 2010-20114
  • Chart Sales Value and Market Share of Insulin Detemir Injection in China, 2010-2014
  • Chart Price of Insulin Detemir Made by Novo Nordisk (Denmark) in Some Regions in China
Back to Top